Biotech

MethylGene Announces the Appointment of Peggy Mulligan to its Board of Directors

MONTREAL, QUEBEC: MONTREAL, QUEBEC -- (Marketwire) -- 03/19/12 -- MethylGene Inc. (TSX: MYG) today announced the appointment of Peggy Mulligan, FCA to the Company's Board of Directors."Peggy is a financial ...

Marina Biotech, Inc. to Raise $1.2 Million in Registered Direct Offering

BOTHELL, WA: BOTHELL, WA -- (Marketwire) -- 03/19/12 -- Marina Biotech, Inc. (OTCQX: MRNA), a leading nucleic acid-based drug discovery and development company, announced that it has entered into definitive agre ...

Cellceutix Enters Into a Collaborative Agreement With Beth Israel Deaconess Medical Center for Pro-Apoptotic Function of p53 in Melanoma and Renal Cell Carcinoma

BEVERLY, MA: BEVERLY, MA -- (Marketwire) -- 03/19/12 -- Cellceutix Corporation (OTCBB: CTIX) ("the Company"), a biopharmaceutical company focused on discovering and developing small molecule drugs to t ...

SOHM, Inc. Entering the Huge USA Generic Pharmaceutical Market

BUENA PARK, CA: SOHM, Inc. Aggressively Working Towards Entering the Huge Generic Pharmaceutical Market of USA ...

Titan Pharmaceuticals Announces Fourth Quarter and Year-End 2011 Financial Results

SOUTH SAN FRANCISCO, CA: Titan Management Team to Host Conference Call March 20 at 11:00 a.m. PT/2:00 p.m. ET ...

Arch Awarded Funding from the Government of Canada to Develop Brain Tumour Targeting Technology

TORONTO, CANADA: TORONTO, CANADA -- (Marketwire) -- 03/15/12 -- Arch Biopartners Inc. ("Arch" or the "Company") (CNSX: ACH)(OTCBB: FOIFF) today announced that the National Research Council of Can ...

Agennix AG Reports Financial Results for Fiscal Year 2011

PLANEGG, GERMANY and MUNICH, GERMANY and PRINCETON, NJ and HOUSTON, TX: Provides Update on Lead Product Candidate, Oral Talactoferrin ...

Threshold Pharmaceuticals Doses First Patient in Clinical Trial Evaluating TH-302 in Multiple Myeloma

SOUTH SAN FRANCISCO, CA: SOUTH SAN FRANCISCO, CA -- (Marketwire) -- 03/14/12 -- Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that the first patient has been dosed in its Phase 1/2 clinical trial of TH-302 ...

2012 North American Pharmaceutical & Biotech Industry Outlook Spotlights $15 Billion in Capital Spending, an Industrial Info News Alert

SUGAR LAND, TX: SUGAR LAND, TX -- (Marketwire) -- 03/14/12 -- Reported by Annette Kreuger, Industrial Info Resources (Sugar Land, Texas) -- Industrial Info Resources is pleased to announce the release of the . With ...

Novo Energies Corporation Announces That Dr. Michael Har-Noy Has Been Invited to Be a Guest Speaker at the 11th Annual National Cancer Conference in Thailand

NEW YORK, NY: NEW YORK, NY -- (Marketwire) -- 03/14/12 -- Novo Energies Corporation ("Novo") (OTCBB: NVNC) today announced that Dr. Michael Har-Noy, the Founder and Chief Executive Officer of Immunovati ...